JSC «Grindeks» recently announced it will be investing 1.6 million lats in its quality control laboratory, out of which 1.33 million lats will be invested in the construction, but more than 270 thousand lats in the modern quality control equipment.
The new laboratory will perform pharmaceutical analyses, development and validation of analytical methods. All activities in the laboratory will conform to principles of Good Manufacturing Practice (GMP), ISO 9001 and ISO 14001.
By expanding opportunities of quality control, «Grindeks» will provide analytical services for Latvia's and foreign companies and perform analyses of pharmaceutical products – final dosage forms (tablets, capsules, ointments, gels, syrups,solutions for injections), API's, as well as the analysis of technological experiments and cleaning validation. The company will perform batch release of pharmaceutical products for EU and CIS countries.
Dr.chem Juris Hmelnickis, Quality director at JSC «Grindeks» said: "The quality requirements in the pharmaceutical industry and the area of Good Manufacturing Practice increase every year. Producing medications and recognizing our important mission of caring for people's health, «Grindeks» constantly improves the performance in the quality field. This project will strengthen «Grindeks» positions and increase our competitiveness. In addition, it will open up opportunities to provide analytical services to other companies in Latvia and abroad.”
The laboratory project is being implemented in several stages and is expected to be completed in May, 2014.
According to the project plan, the microbiology laboratory area will be 250m², but the quality control laboratory will have a total area of 700m². A modern automatic control system will be installed in the laboratory that regulates the microclimate and engineering systems, as well as saving energy resources.
